<DOC>
	<DOCNO>NCT00254436</DOCNO>
	<brief_summary>To demonstrate effectiveness epoetin alfa reduction red blood cell transfusion gastric rectal cancer patient undergo preoperative chemoradiation therapy follow surgery .</brief_summary>
	<brief_title>A Double-Blind , Randomized , Placebo-Controlled Study Efficacy Safety Weekly Procrit Given Gastric Rectal Patients</brief_title>
	<detailed_description>Anemia fatigue common problem gastric rectal cancer subject completion chemoradiation therapy surgery . Results several study cancer subject suggest treatment epoetin alfa may effective maintain hemoglobin level , thereby reduce fatigue , decrease transfusion requirement , potentially improve quality life .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Male female 18 year age old Must confirm diagnosis gastric rectal cancer treatment plan preoperative chemoradiation follow surgery Must baseline hemoglobin &gt; /= 10 g/dl &lt; 15 g/dl Must adequate hematologic function Must life expectancy 6 month Karnofsky performance status least 50 % Must adequate renal function Patients reproductive potential must use adequate contraceptive method treatment three month complete treatment Patients must able read , understand , complete three Quality Life questionnaires English . Prior chemotherapy patient rectal cancer Gastric cancer patient receive 2 cycle chemotherapy Anemia due factor cancer/chemotherapy Patients prior treatment epoetin alfa investigational form erythropoietin within previous 6 month Known hypersensitivity mammaliancell derive product human albumin Pregnant lactate woman Untreated Central Nervous System metastases Any significant , uncontrolled disease/dysfunction major organ Uncontrolled hypertension history uncontrolled cardiac arrhythmia , pulmonary embolism , thrombosis New onset poorly control seizure History active second malignancy Major infection require hospitalization antibiotic surgery within 14 day study entry Blood transfusion within 1 month study entry Androgen therapy within 2 month study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Epoetin Alfa</keyword>
	<keyword>Epogen</keyword>
	<keyword>Erythropoietin</keyword>
</DOC>